A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

NCT06330064 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

520

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent or Metastatic Solid Tumors

Interventions

DRUG: Ifinatamab deruxtecan

Sponsor

Daiichi Sankyo

Collaborators

[object Object]